Therapeutic approaches to combating lipoatrophy: Do they work?

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 5, 2005, Pages 612-615

  Martin, Allison ^a   Mallon, Patrick W G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiretroviral therapy; Body composition; HIV; Hyperlipidaemia; Lipodystrophy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTILIPEMIC AGENT; DIDANOSINE; GEMFIBROZIL; GROWTH HORMONE; LAMIVUDINE; METFORMIN; NUCLEOSIDE ANALOG; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADIPOSE TISSUE; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; DRUG WITHDRAWAL; ESTHETIC SURGERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IN VITRO STUDY; INHIBITION KINETICS; INSULIN RESISTANCE; LIPOATROPHY; LIPODYSTROPHY; PATHOGENESIS; SUBCUTANEOUS TISSUE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 18844428017     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki062     Document Type: Article

References (37)

1. Miller, J., Carr, A., Emery, S. et al. (2003). HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Medicine 4, 293-301.
2. Timar, O., Sestier, F. & Levy, E. (2000). Metabolic syndrome X: a review. Canadian Journal of Cardiology 16, 779-89.
3. Carrieri, P., Cailleton, V., Le Moing, V. et al. (2001). The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndromes 28, 232-9.
4. Moorman, A., Holmberg, S., Marlowe, S. et al. (1999). Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS). Annals of Epidemiology 9, 349-57.
5. Bastard, J., Caron, M., Vidal, H. et al (2002). Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359, 1026-31.
6. Martinez, E., Conget, I., Lozano, L. et al. (1999). Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13, 805-10.
7. Carr, A., Hudson, J., Chuah, J. et al. (2001). HIV protease inhibitor substitution in patients with lipodystrophy: a randomised, controlled, open-label, multicentre study. AIDS 15, 1811-22.
8. Martin, A., Smith, D., Carr, A. et al. (2004). Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomised clinical trial (The PIILR Study). HIV Clinical Trials 5, 192-200.
9. Ruiz, L., Negredo, E., Domingo, P. et al. (2001). Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicentre, randomised, controlled study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 27, 229-36.
10. Saint-Marc, T., Partisani, M., Poizot-Martin, I. et al. (1999). A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13, 1659-67.
11. Mallal, S., John, M., Moore, C. et al. (2000). Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14, 1309-16.
12. Mallon, P., Miller, J., Cooper, D. et al. (2003). Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 17, 971-9.
13. Lewis, W. & Dalakas, M. (1995). Mitochondrial toxicity of antiviral drugs. Nature Medicine 1, 417-22.
14. Brinkman, K., Smeitink, J., Romijn, J. et al. (1999). Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354, 1112-5.
15. Shikuma, C., Hu, N., Milne, C. et al. (2001). Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 15, 1801-9.
16. Pace, C., Martin, A., Hammond, E. et al. (2003). Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antiviral Therapy 8, 323-31.
17. Nolan, D., Hammond, E., James, I. et al. (2003) Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiviral Therapy 8 617-26.
18. van der Valk, M., Casula, M., Weverlingz, G. et al. (2004). Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antiviral Therapy 9, 385-93.
19. Carr, A., Workman, C., Smith, D. et al. (2002). Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomised trial. Journal of the American Medical Association 288, 207-15.
20. Martin, A., Smith, D., Carr, A. et al. (2004). Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study. AIDS 18, 1029-36.
21. Smith, D., Carr, A., Law, M. et al. (2002). Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study. AIDS 16, 2489-91.
22. Moyle, G., Baldwin, C., Langroudi, B. et al. (2003). A 48-week, randomised, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. Journal of Acquired Immune Deficiency Syndromes 33, 22-8.
23. John, M., McKinnon, E., James, I. et al. (2003). Randomised, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 33, 29-33.
24. Shlay, J.C., Visnegarwala, F., Bartsch, G., et al. (2003) Rates of change in body composition among antiretroviral-naive HIV-infected patients randomized to didanosine/stavudine versus abacavir/lamivudine containing regimen in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) study (CPCRA 058). In Programme and Abstracts of the Fifth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris , France, 2003. Antiviral Therapy 8, L12, Abstract 13.
25. Gallant, J. E., Staszewski, S., Pozniak, A. L. et al. (2004). Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Journal of the American Medical Association 292, 191-201.
26. Chaput, E., Saladin, R., Silvestre, M. et al. (2000). Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochemical and Biophysical Research Communications 271, 445-50.
27. Arioglu, E., Duncan-Morin, J., Sebring, N. et al. (2000). Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Annals of Internal Medicine 133, 263-74.
28. Hadigan, C., Yawetz, S., Thomas, A. et al. (2004). Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomised, controlled trial. Annals of Internal Medicine 140, 786-94.
29. Carr, A., Workman, C., Carey, D. et al. (2004). No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363, 429-38.
30. Levan, P., Nguyen, T. H., Lallemand, F. et al. (2002). Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS 16, 1985-7.
31. Guaraldi, G., Orlando, G., De Fazio, D., et al. (2004) Long-term follow-up of graft hypertrophy after autologous fat transfer for HIV-related face lipoatrophy (hamster syndrome 1 year later). In Programme and Abstracts of the Sixth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Washington, DC, 2004. Antiviral Therapy 9, L52, Abstract 90.
32. Valantin, M. A., Aubron-Olivier, C., Ghosn, J. et al. (2003). Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 17, 2471-7.
33. Hadigan, C., Corcoran, C., Basgoz, N. et al. (2000). Metformin in the treatment of HIV lipodystrophy syndrome: a randomised controlled trial. Journal of the American Medical Association 284, 472-7.
34. Miller, J., Brown, D., Amin, J. et al. (2002). A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 16, 2195-200.
35. Moyle, G., Lloyd, M., Reynolds, B. et al. (2001). Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 15, 1503-8.
36. Wanke, C., Gerrior, J., Kantaros, J. et al. (1999). Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13, 2099-103.
37. Koutkia, P., Canavan, B., Breu, J. et al. (2004). Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. Journal of the American Medical Association 292, 210-8.